Douketis JD, Spyropoulos AC. Perioperative Management of Anticoagulant and Antiplatelet Therapy. NEJM Evid. 2023 Jun;2(6):EVIDra2200322. doi: 10.1056/EVIDra2200322. Epub 2023 May 23. PMID: 38320132.
Douketis JD, Spyropoulos AC, Murad MH, et al. Perioperative Management of Antithrombotic Therapy: An American College of Chest Physicians Clinical Practice Guideline. Chest. 2022 Nov;162(5):e207-e243. doi: 10.1016/j.chest.2022.07.025. Epub 2022 Aug 11. Erratum in: Chest. 2023 Jul;164(1):267. doi: 10.1016/j.chest.2023.05.019. PMID: 35964704.
Steffel J, Collins R, Antz M, et al. 2021 European Heart Rhythm Association Practical Guide on the Use of Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation. Europace. 2021 Oct 9;23(10):1612-1676. doi: 10.1093/europace/euab065. PMID: 33895845.
Farge D, Frere C, Connors JM, et al; International Initiative on Thrombosis and Cancer (ITAC) advisory panel. 2019 international clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. Lancet Oncol. 2019 Oct;20(10):e566-e581. doi: 10.1016/S1470-2045(19)30336-5. Epub 2019 Sep 3. PMID: 31492632.
Douketis JD, Spyropoulos AC, Duncan J, et al. Perioperative Management of Patients With Atrial Fibrillation Receiving a Direct Oral Anticoagulant. JAMA Intern Med. 2019 Nov 1;179(11):1469-1478. doi: 10.1001/jamainternmed.2019.2431. PMID: 31380891; PMCID: PMC6686768.
January CT, L Wann LS, Calkins H, et al. 2019 AHA/ACC/HRS Focused Update of the 2014 AHA/ACC/HRS Guideline for the Management of Patients With Atrial Fibrillation: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines and the Heart Rhythm Society in Collaboration With the Society of Thoracic Surgeons. Circulation. 2019 Jul 9;140(2):e125-e151. doi: 10.1161/CIR.0000000000000665. Epub 2019 Jan 28. PMID: 30686041.
Horlocker TT, Vandermeuelen E, Kopp SL, Gogarten W, Leffert LR, Benzon HT. Regional Anesthesia in the Patient Receiving Antithrombotic or Thrombolytic Therapy: American Society of Regional Anesthesia and Pain Medicine Evidence-Based Guidelines (Fourth Edition). Reg Anesth Pain Med. 2018 Apr;43(3):263-309. doi: 10.1097/AAP.0000000000000763. Review. Erratum in: Reg Anesth Pain Med. 2018 Jul;43(5):566. Vandermeuelen, Erik [corrected to Vandermeulen, Erik]. PMID: 29561531.
Spyropoulos AC, Al-Badri A, Sherwood MW, Douketis JD. Periprocedural management of patients receiving a vitamin K antagonist or a direct oral anticoagulant requiring an elective procedure or surgery. J Thromb Haemost. 2016 May;14(5):875-85. doi: 10.1111/jth.13305. Epub 2016 Apr 7. Review. PMID: 26988871.
Baglin T, Hillarp A, Tripodi A, Elalamy I, Buller H, Ageno W. Measuring Oral Direct Inhibitors (ODIs) of thrombin and factor Xa: A recommendation from the Subcommittee on Control of Anticoagulation of the Scientific and Standardisation Committee of the International Society on Thrombosis and Haemostasis. J Thromb Haemost. 2013 Jan 24. doi: 10.1111/jth.12149. [Epub ahead of print] PMID: 23347120.
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence Based Clinical Practice Guidelines. Chest. 2012 Feb; 141 (2 Suppl): e1S-e801S.
1. Perispinal hematoma (hematoma of the spinal canal) after a central blockade (ie, epidural or spinal anesthesia) is a rare but serious complication of anticoagulant treatment and antithrombotic prophylaxis.
Risk factors: Impaired hemostasis (including procedures performed at the time of full anticoagulant activity), anatomic abnormalities of the spine, catheter use, traumatic or repeated attempts to introduce a needle or catheter into the spinal canal, and catheter removal at the time of anticoagulant activity.
2. Timing of lumbar puncture, removal of an epidural or spinal catheter, and start of anticoagulant prophylaxis after an epidural or spinal anesthesia in patients treated with anticoagulants: Table 1. Also see Perioperative Direct Oral Anticoagulant (DOAC) Management.
TablesTop
Agent |
Lumbar puncture (with or without catheter introduction) |
Removal of epidural or spinal catheter in patients treated with anticoagulantsb |
Starting antithrombotic prophylaxis after spinal or epidural anesthesia |
ASA |
No restrictions |
No restrictions |
No restrictions |
Clopidogrel |
≥7 days from drug discontinuation (min 5) |
– |
After catheter removal |
Prasugrel |
≥10 days from drug discontinuation (min 7) |
≥10 days from drug discontinuation |
After catheter removal |
Ticagrelor |
≥5 days from drug discontinuation (min 3) |
– |
After catheter removal |
VKAc |
4 days from drug discontinuation + normal INR |
When INR <1.5 |
After catheter removal |
UFH IV |
4 h after discontinuation of IV infusion and aPTT normalization |
4 h after discontinuation of infusion and aPTT normalization |
– >2 h after catheter removal – Defer by 12 h in case of bloody puncture (applies to intraoperative use of IV UFH) |
UFH SC |
4 h after SC injection of prophylactic dose |
4 h after SC injection of prophylactic dose |
1 h after catheter removal |
LMWH SC |
– 10-12 h after standard prophylactic dose – 24 h after last therapeutic dose and after normalization of anti-Xa activity |
– 10-12 h after last dose and 4 h before next dose – 24 h after last dose (with doses administered every 24 h) |
– 2-4 h after catheter removal – Defer by 24 h in case of bloody puncture (applies to therapeutic dose) |
Fondaparinux |
– 24-36 h after standard prophylactic dose (2.5 mg SC every 24 h) – 48-72 h after standard therapeutic dose (7.5 mg SC every 24 h) |
36-42 h after last dose (no data available on safety of fondaparinux in patients with indwelling spinal or epidural catheters; other anticoagulants should be used) |
– 6-12 h after catheter removal in patients receiving prophylactic doses (2.5 mg SC every 24 h) – 12-24 h after catheter removal in patients receiving therapeutic doses (7.5 mg SC every 24 h) or patients at high bleeding risk |
Factor Xa inhibitor (oral)d |
Hold day of procedure and 2 days prior (>48 h after last dose) |
Hold day of procedure and 2 days prior (>48 h after last dose) |
6-12 h after catheter removal in patients starting prophylactic dosesf ≥24 h after removal of catheter in patients resuming therapeutic dosesg |
Direct thrombin inhibitor (oral)e |
Hold day of procedure and 2 days prior (>48 h after last dose; hold 4 days if CrCl <50 mL/min) |
Hold day of procedure and 2 days prior (>48 h after last dose; hold 4 days if CrCl <50 mL/min) |
6-12 h after catheter removal in patients starting prophylactic dosesh ≥24 h after catheter removal in patients resuming therapeutic dosesi |
a No high-quality data is available for oral direct factor Xa inhibitors or thrombin inhibitors. b Applies to patients with normal renal function. c Acenocoumarol and warfarin. d Apixaban, edoxaban, and rivaroxaban. e Dabigatran. f Apixaban 2.5 mg bid, edoxaban 30 mg once daily, or rivaroxaban 10 mg once daily. g Apixaban 5 mg bid, edoxaban 60 mg once daily, or rivaroxaban 20 mg once daily. h Dabigatran 150-220 mg once daily. i Dabigatran 110-150 mg bid. | |||
aPTT, activated partial thromboplastin time; ASA, acetylsalicylic acid; bid, 2 times a day; CrCl, creatinine clearance; INR, international normalized ratio; IV, intravenous; LMWH, low-molecular-weight heparin; SC, subcutaneous; UFH, unfractionated heparin; VKA, vitamin K antagonist. |